The EASL Policy Statement on liver cancer screening has recently been updated.

In addition to addressing the updates, this episode of EASL Studio will discuss how risk-based surveillance of hepatocellular carcinoma (HCC) in patients suffering from cirrhosis is a cost effective strategy to increase benefits, reduce the harm of HCC surveillance.


  • Prof. Thomas Berg (Moderator)
  • Mr. Pietro Fiocchi (Faculty)
  • Prof. Peter Jepsen (Faculty)
  • Mrs. José Willemse (Patient Perspective) 

ℹ️ Please click here to access the podcast version of this EASL Studio episode.


Log in to post comments